Our dedication to discovery remains unwavering after more than 30 years of investigating potential life-changing treatments for patients with neurological, neuroendocrine, and neuropsychiatric disorders.

USC-Neurocrine Biosciences Pharmaceutical Industry Fellowship Programs—We offer a variety of fellowship opportunities across Medical and Regulatory Affairs, including Field Medical Affairs/Medical Science Liaison (MSL–2 years), Medical Communications (1 year), Medical Training (1 year), and Regulatory Affairs (2 years). These programs are ...

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. [1] It is headquartered in San Diego, California, and led by CEO Kevin Gorman. [3] Neurocrine develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine was founded in 1992 by Wylie Vale, Ph.D., of the Salk Institute for Biological Studies, where he contributed to Nobel Prize–winning work in endocrinology, and award-winning Stanford University neurologist Lawrence Steinman, Ph.D.

5 天之前 · Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. ...

2024年8月28日 · Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.

Neurocrine Biosciences | 67,791 followers on LinkedIn. You Deserve Brave Science | Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple...

2024年12月13日 · The U.S. Food and Drug Administration has approved Neurocrine Biosciences' drug to treat a type of genetic disorder, the health regulator's website showed on Friday.

SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).

2024年7月1日 · Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for ...